Analytical Data
-
Gene name
HACE1
- Application
-
Alternative Names
HACE1; E3 ubiquitin-protein ligase HACE1; HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1; HECT-type E3 ubiquitin transferase HACE1
-
Species
Human
-
Source
E. coli
-
Tag
N-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IYU2
-
Expression Region
E2-A909
-
Protein Length
Partial
-
Molecular Weight
104.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HACE1 (HECT domain and ankyrin repeat-containing protein 1) is an E3 ubiquitin ligase that plays a crucial role in various cellular processes, including protein degradation, cell proliferation, and apoptosis. Research into HACE1 has gained momentum due to its involvement in tumorigenesis and cancer progression, particularly in the context of human malignancies. Studies have indicated that HACE1 functions as a tumor suppressor; its downregulation or loss of function is often correlated with aggressive cancer phenotypes. Moreover, HACE1 has been implicated in the regulation of the immune response and inflammatory pathways, further linking it to diseases beyond cancer. The understanding of HACE1’s mechanisms presents potential therapeutic avenues, particularly in enhancing cancer treatments or modulating immune responses. The recombinant expression of HACE1 protein allows for detailed investigations into its biochemical functions, interactions, and structural properties, facilitating the development of targeted strategies for disease intervention. Thus, ongoing research into HACE1 recombinant protein not only aids in deciphering its biological roles but also holds promise for innovative therapeutic approaches in oncology and immunology.
